EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Onabotulinum toxin A block of the sphenopalatine ganglion in patients with persistent idiopathic facial pain: a randomized, triple-blind, placebo-controlled, exploratory, cross-over study

Kent A Jamtøy, Wenche M Thorstensen iD, Lars J Stovner, Annika Rosén, Stine Maarbjerg, Daniel Bratbak, Melanie R Simpson, Erling Tronvik

Cephalalgia · 2023-07 · 43 (7)

DOI: 10.1177/03331024231187132 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, online erschienen am 12.07.2023. Verfasst von Kent A Jamtøy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Maxillofacial Surgery, St Olavs University Hospital, Trondheim, Norway. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Ganglia, Parasympathetic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Teknisk-Naturvitenskapelige Universitet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the efficacy and safety of injecting onabotulinum toxin A (BTA) towards the sphenopalatine ganglion (SPG) using the MultiGuide® in patients with persistent idiopathic facial pain (PIFP).

Methods

This cross-over, exploratory study compared the injection of 25 units BTA versus placebo in patients who met modified ICDH-3 criteria for PIFP. Daily pain diaries were registered for a 4-week baseline, a 12-week follow-up after each injection, and an 8-week conceptual washout period in between. The primary efficacy endpoint was the change from baseline to weeks 5–8 in average pain intensity using a numeric rating scale. Adverse events were recorded.

Results

Of 30 patients who were randomized to treatment, 29 were evaluable. In weeks 5–8, there was no statistically significant difference in average pain intensity between BTA versus placebo (0.00; 95% CI = −0.57 to 0.57) ( P = 0.996). Following both BTA and placebo injections, five participants reported at least a 30% reduction in average pain during weeks 5–8 ( P = 1.000). No serious adverse events were reported. Post-hoc analyses indicated a possible carry-over effect.

Conclusions

Injection of BTA toward the SPG with the MultiGuide® did not appear to provide a reduction in pain reduction at 5–8 weeks, although this finding may be influenced by a carry-over effect. The injection appears to otherwise be safe and well-tolerated in patients with PIFP. Trial Registration: The study protocol is registered in ClinicalTrial.gov (NCT03462290) and EUDRACT (number: 2017-002518-30).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AGanglia, ParasympatheticHumansCross-Over StudiesFacial Pain

Stichwörter der Autor:innen

Botoxatypical facial painbotulinum toxin type Apterygopalatine fossatrigeminal nerve

Substanzen

onabotulinum toxin ABotulinum Toxins, Type A

Autor:innen und Institutionen

  • Department of Maxillofacial Surgery, St Olavs University Hospital, Trondheim, Norway.
  • Department of Neuromedicine and Movement Science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Otolaryngology, Head and Neck Surgery, St Olavs University Hospital, Trondheim, Norway.
  • Norwegian Advisory Unit on Headaches, Department of Neurology and Clinical Neurophysiology, St Olavs University Hospital, Trondheim, Norway.
  • Department of Clinical Dentistry, University of Bergen, Bergen, Norway.
  • Department of Oral and Maxillofacial Surgery, Haukelands University Hospital, Bergen, Norway.

ORCID-Profile: Wenche M Thorstensen

Förderung

  • Norges Teknisk-Naturvitenskapelige Universitet

Zitieren

APA

Jamtøy, K. A., Thorstensen, W. M., Stovner, L. J., Rosén, A., Maarbjerg, S., Bratbak, D., Simpson, M. R., & Tronvik, E. (2023). Onabotulinum toxin A block of the sphenopalatine ganglion in patients with persistent idiopathic facial pain: a randomized, triple-blind, placebo-controlled, exploratory, cross-over study. Cephalalgia, 43(7). https://doi.org/10.1177/03331024231187132

Vancouver

Jamtøy KA, Thorstensen WM, Stovner LJ, Rosén A, Maarbjerg S, Bratbak D, et al. Onabotulinum toxin A block of the sphenopalatine ganglion in patients with persistent idiopathic facial pain: a randomized, triple-blind, placebo-controlled, exploratory, cross-over study. Cephalalgia. 2023;43(7). doi:10.1177/03331024231187132

BibTeX
@article{Jamty2023,
  author = {Jamtøy, Kent A and Thorstensen, Wenche M and Stovner, Lars J and Rosén, Annika and Maarbjerg, Stine and Bratbak, Daniel and Simpson, Melanie R and Tronvik, Erling},
  title = {Onabotulinum toxin A block of the sphenopalatine ganglion in patients with persistent idiopathic facial pain: a randomized, triple-blind, placebo-controlled, exploratory, cross-over study},
  journal = {Cephalalgia},
  year = {2023},
  volume = {43},
  number = {7},
  doi = {10.1177/03331024231187132}
}
Kostenlos starten →